Scimplify’s $25 million funding round is not only a startup financing event. It is also a test of whether India can turn advanced-materials research into dependable, qualified manufacturing capacity. The Bengaluru-based company says it will use the capital to expand research, processing and partner-manufacturing capabilities, while building a physical presence in the United States for rare earths, critical metals, semiconductor chemicals and battery chemicals.
The round, led by Hitachi Ventures, includes participation from Teknor Apex, Henkel and a Japanese chemical company. Existing investors Accel, Bertelsmann India Investments, 3one4 Capital and Omnivore also participated. With this investment, Scimplify says it has raised $80 million across its disclosed funding rounds.
The immediate commercial plan is clear. Scimplify intends to build physical processing capabilities in the US and simultaneously qualify American manufacturing partners that can support technology transfer, pilot batches and validation batches. Its current R&D facilities are in Bengaluru and Hyderabad, and its expansion will be supported by SciNode, an artificial-intelligence platform designed for synthesis-route prediction, factory-production simulation and coordination across research, quality, sourcing and regulatory workflows.
The larger issue is the distance between discovering a material and producing it reliably. According to the report, new materials for batteries, semiconductors, energy infrastructure and life sciences may be demonstrated in laboratories but still struggle to reach dependable commercial production. That gap is not simply a question of factory space. It involves process engineering, quality systems, regulatory compliance, supplier qualification and the ability to repeat a process at the required scale.
Scimplify was founded in 2023 by Sachin Santhosh, Salil Srivastava, Dheeraj Dhingra and Hersh Manek to address that transition. Rather than developing new materials itself, the company works with innovators that have already demonstrated a material in the laboratory but do not have a reliable route to production. Its model combines process development with manufacturing rather than treating them as separate stages.
That positioning matters because advanced materials are difficult to commercialise through a simple contract-manufacturing arrangement. A customer may require a particular purity, batch consistency or production method. The process may need to be adapted repeatedly before it can be transferred to a manufacturing partner. Pilot and validation batches are therefore not just smaller production runs; they are part of establishing whether the process is technically repeatable and acceptable to the eventual customer.
The funding will support research facilities staffed by scientists and process engineers, additional processing facilities, an expanded manufacturing-partner network and further development of SciNode. These investments indicate that Scimplify is building an operating system around industrialisation rather than offering only a marketplace for chemical production. The company’s stated objective is to connect technical development, sourcing, manufacturing and regulatory workflows in one system.
The company’s US plan also shows why geography remains important even in a digitally coordinated manufacturing model. Scimplify says the first phase will focus on chemistries where domestic processing capabilities in the US remain limited. The company plans to combine its own physical processing capacity with qualified American partners capable of technology transfer and pilot and validation production. This is a two-part strategy: retain technical control over selected processes while building a local network for production and qualification.
For India, the significance lies in the role assigned to its cities and industrial capabilities. Scimplify’s R&D facilities in Bengaluru and Hyderabad place scientific and process-engineering work inside two established technology and pharmaceutical ecosystems. The company’s model depends on these urban knowledge centres being connected to manufacturing partners, customer requirements and international supply chains. That connection is more demanding than simply locating a laboratory in a major city.
The report quotes Scimplify co-founder Sachin Santhosh as saying that global innovators need more than factories and require technical expertise to manufacture complex materials at scale. The statement captures the company’s central proposition: manufacturing capacity is useful only when it is supported by the scientific and quality systems needed by global customers.
Hitachi Ventures Managing Director of India Radhika Ananth offers a similar explanation from the investor side. She says India has manufacturing capacity, but that some of it is underused and lacks the science and quality systems required by global customers. She also says Scimplify has served customers in more than 40 countries in under three years, while more than 40 per cent of its portfolio is already in advanced materials for semiconductors, batteries and critical minerals. These are statements attributed to the company and investor and are not independently established in the supplied material.
The customer list cited in the report includes Henkel, Coromandel, Dr Reddy’s, Coherent, Holcim, BASF, Sanyo, Marubeni, TDK and Mankind Pharma. The range of names points to the cross-sector character of advanced-materials manufacturing, spanning chemicals, pharmaceuticals, electronics, construction-related products and industrial supply chains. It also shows why the company’s proposed platform must coordinate more than one type of manufacturing requirement.
The industrial policy question is whether firms such as Scimplify can make the transition from fragmented capacity to integrated production systems. The challenge described in the report is not a lack of laboratory ideas alone. It is the absence of a dependable pathway from laboratory validation to pilot manufacturing, customer qualification and commercial supply. That pathway requires companies, technical institutions, manufacturing partners and regulators to work through the same process rather than operate as disconnected stages.
SciNode is intended to provide a digital layer across this pathway. Its functions, as described by the company, include predicting synthesis routes, simulating factory production and coordinating R&D, quality, sourcing and regulatory activities. The platform may help organise complex workflows, but the supplied material does not establish how accurately it performs these functions, how widely it is deployed or whether it has reduced production timelines or costs. Those outcomes remain matters to be demonstrated as the company expands.
The same caution applies to the proposed physical infrastructure. Scimplify has said it will build processing capabilities in the US, but the report does not provide facility locations, investment values, production capacities, construction timelines or employment estimates. It also does not specify which American manufacturing partners have been qualified. The announcement therefore establishes the direction of expansion, not its final industrial footprint.
The funding round nevertheless identifies a measurable shift in the company’s ambition. Scimplify is moving from an India-based R&D and partner-manufacturing model towards a system with direct processing capabilities in the US and a broader international network. The disclosed $80 million raised across funding rounds provides financial backing for that expansion, although the report does not state how the latest capital will be divided between research, facilities, software development and market expansion.
The deeper urban question is how cities can support industries that sit between science and manufacturing. Such companies require laboratories, specialised engineering talent, industrial land, compliant production facilities, reliable suppliers and access to international customers. They also require institutions capable of handling technology transfer and regulatory qualification. A city may possess some of these assets without having the connections that allow them to function as one industrial system.
Scimplify’s Bengaluru and Hyderabad operations, combined with its planned US capabilities, provide one example of that distributed model. Scientific work can remain anchored in Indian cities while processing, qualification and customer access are organised across multiple geographies. The model could make industrial networks more flexible, but it also makes coordination and quality assurance central to the business.
What the funding confirms is that investors and industrial companies see a commercial gap in advanced-materials manufacturing and believe Scimplify can address part of it. What remains unestablished is the scale at which the model can operate, the capacity of its planned US facilities, the performance of its partner network and the extent to which SciNode improves industrial execution. The next evidence will come from the company’s facility build-out, partner qualifications, customer production programmes and expansion across critical materials and advanced manufacturing.
